Novo Nordisk Inc v. Orbicular Pharmaceutical Tech Pvt Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: Orbicular Pharmaceutical Technologies Pvt. Ltd. (India), Cipla Ltd. (India), and Cipla USA, Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:22-cv-00856, D. Del., 06/23/23
• Venue Allegations: Venue is alleged to be proper based on Defendants conducting business, deriving revenue, and distributing generic pharmaceutical products in Delaware, as well as having engaged in systematic and continuous contacts with the state.
• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Saxenda® (liraglutide) product constitutes infringement of four U.S. patents covering the drug's formulation and its injection pen device.
• Technical Context: The technology relates to pharmaceutical formulations for peptide drugs and the mechanical systems within pen-style injection devices used for self-administration, particularly for weight management treatments.
• Key Procedural History: This is a consolidated ANDA action initiated after Defendants Orbicular and Cipla filed an ANDA seeking FDA approval to market a generic version of Saxenda® and sent Paragraph IV certifications asserting non-infringement, unenforceability, or invalidity of the asserted patents. Plaintiffs previously asserted a larger set of patents, many of which have been dismissed from the current amended complaint, though Plaintiffs reserve the right to re-assert them.

Case Timeline

Date	Event
2003-11-20	U.S. Patent 8,114,833 Priority Date
2005-07-27	U.S. Patent 8,920,383 Priority Date
2005-07-27	U.S. Patent 9,775,953 Priority Date
2007-02-05	U.S. Patent 9,265,893 Priority Date
2012-02-14	U.S. Patent 8114833 Issue Date
2014-12-30	U.S. Patent 8920383 Issue Date
2016-02-23	U.S. Patent 9265893 Issue Date
2017-10-03	U.S. Patent 9775953 Issue Date
2022-05-13	Defendants send First Notice Letter with Paragraph IV Certification
2022-06-09	Defendants send Second Notice Letter with amended Paragraph IV Certification
2023-06-23	Second Amended Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,114,833

• Patent Identification: U.S. Patent No. 8,114,833, "Propylene Glycol-Containing Peptide Formulations Which Are Optimal for Production and for Use in Injection Devices," issued February 14, 2012.

The Invention Explained

• Problem Addressed: The patent's background describes that mannitol, a common isotonicity agent in peptide-based pharmaceutical formulations, can crystallize, leading to deposits in production equipment and clogging of injection needles, which reduces manufacturing efficiency and poses a risk to patients '833 Patent, col. 1:30-49
• The Patented Solution: The invention replaces the problematic mannitol with propylene glycol as the isotonicity agent in peptide formulations, particularly for GLP-1 agonists '833 Patent, abstract The specification provides experimental data and figures suggesting that this substitution reduces deposits and clogging, making the formulation more suitable for both production and use in injection devices '833 Patent, col. 2:1-10 '833 Patent, FIG. 7
• Technical Importance: The invention provided a more robust and reliable formulation for injectable peptide drugs, enhancing manufacturing yield and improving the safety and consistency of drug delivery for patients using pen injectors '833 Patent, col. 2:11-20

Key Claims at a Glance

• The complaint asserts infringement of claims 1-31 Compl. ¶40 Independent claim 1 is asserted.
• The essential elements of independent claim 1 include:
  • A pharmaceutical formulation comprising at least one GLP-1 agonist,
  • a disodium phosphate dihydrate buffer and
  • propylene glycol,
  • wherein said propylene glycol is present in said formulation in a final concentration of from about 1 mg/ml to about 100 mg/ml
  • and wherein said formulation has a pH of from about 7.0 to about 10.0.
• The complaint notes that claims 16-31 are directed to methods of preparation Compl. ¶40

U.S. Patent No. 8,920,383

• Patent Identification: U.S. Patent No. 8,920,383, "Dose Mechanism for an Injection Device for Limiting a Dose Setting Corresponding to the Amount of Medicament Left," issued December 30, 2014.

The Invention Explained

• Problem Addressed: In drug injection devices, it is critical to ensure that a user cannot set a dose that exceeds the amount of medicament remaining in the drug reservoir, as doing so could lead to incorrect dosing with serious health consequences '383 Patent, col. 1:27-35
• The Patented Solution: The patent discloses an "end-of-content" mechanical stop for a pen-style injector. The mechanism uses a threaded piston rod, a driver coupled to the dose setting member, and a "limiter" that moves along the piston rod's thread as a dose is set '383 Patent, abstract As the drug is used, the total available travel for the limiter decreases until it reaches a stopping position, physically preventing the user from dialing a dose larger than the remaining volume '383 Patent, col. 2:1-18
• Technical Importance: This invention provides a compact and reliable safety feature integrated within an injection pen to prevent a patient from accidentally administering an incomplete dose.

Key Claims at a Glance

• The complaint asserts infringement of claims 1-13 Compl. ¶46 Independent claim 1 is asserted.
• The essential elements of independent claim 1 include:
  • A mechanism for preventing setting of a dose which exceeds the amount of a medicament in a reservoir... comprising:
  • a piston rod having a threaded outer surface, wherein the piston rod rotates and translates axially forward during expelling of medication;
  • a limiter that prevents the setting of a dose which exceeds the amount of medication in a reservoir... the limiter defining a passage for the piston rod;
  • a driver defining a passage for the limiter, the driver being coupled to the dose setting member such that rotation of the dose setting member during dose setting causes the driver to rotate; and
  • wherein the limiter is coupled to the driver and the piston rod such that relative rotation between the driver and the piston rod during dose setting causes the limiter to move towards a stopping position.
• The complaint notes that claim 13 is directed to a syringe device employing such a mechanism Compl. ¶46

Multi-Patent Capsule

• Patent Identification: U.S. Patent No. 9,775,953, "Dose Mechanism for an Injection Device for Limiting a Dose Setting Corresponding to the Amount of Medicament Left," issued October 3, 2017.

• Technology Synopsis: This patent, which shares a specification with the '383 patent, discloses a mechanical "end-of-content" stop for an injection device '953 Patent, abstract It is designed to prevent a user from setting a dose that is larger than the amount of medicament left in the device's reservoir by using a system of a threaded piston rod, a limiter, and a driver that physically blocks the dose setting action when the remaining volume is insufficient '953 Patent, col. 2:1-18

• Asserted Claims: Claims 1-10 and 12-25 are asserted Compl. ¶52

• Accused Features: The end-of-content mechanism within the "Orbicular's Device" used to administer the generic liraglutide product is accused of infringement Compl. ¶¶33, 52

• Patent Identification: U.S. Patent No. 9,265,893, "Injection Button," issued February 23, 2016.

• Technology Synopsis: The patent describes a connection between a push button and a driving part in an injection device, where the two parts rotate relative to each other during dose delivery '893 Patent, abstract The design uses a specific pivot bearing and radial bearings to minimize friction and to manage forces applied off-center to the button, ensuring smooth operation '893 Patent, col. 2:20-33

• Asserted Claims: At least exemplary claim 1 is asserted Compl. ¶58

• Accused Features: The push button connection of the "Orbicular's Device" is accused of infringing the patent Compl. ¶¶57, 59

III. The Accused Instrumentality

Product Identification

• The accused instrumentalities are "Orbicular's Product" and the associated "Orbicular's Device" Compl. ¶¶26, 33

Functionality and Market Context

• The complaint identifies Orbicular's Product as a generic version of liraglutide solution for subcutaneous injection (18 mg/3 ml), intended to be a bioequivalent version of Novo Nordisk's Saxenda® product Compl. ¶¶26, 28 The product is administered using the "Orbicular's Device," a pen-style injector for patient self-administration Compl. ¶33 The complaint includes a redacted visual described as an exemplary schematic of the device from Orbicular's ANDA submission Compl. ¶36 Orbicular's filing of an ANDA for this product prior to the expiration of Plaintiff's patents is the central event triggering the lawsuit Compl. ¶1

IV. Analysis of Infringement Allegations

U.S. Patent No. 8,114,833 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A pharmaceutical formulation comprising at least one GLP-1 agonist,	The complaint alleges Orbicular's Product is a generic version of liraglutide, a GLP-1 agonist, intended to be bioequivalent to Saxenda®, which is covered by the patent.	¶26; ¶28	col. 4:26-33
a disodium phosphate dihydrate buffer	The complaint alleges Orbicular's ANDA submission for a bioequivalent generic version of Saxenda® constitutes infringement, implying the formulation contains the same buffer as the patented product.	¶24; ¶26; ¶40	col. 23:9-12
and propylene glycol,	The complaint alleges the ANDA product is a generic version of Saxenda®, which is covered by the '833 patent. Orbicular did not contest infringement on this basis, only validity.	¶24; ¶40	col. 14:1-10
wherein said propylene glycol is present in said formulation in a final concentration of from about 1 mg/ml to about 100 mg/ml	The infringement allegation is based on the ANDA filing, which seeks approval for a product bioequivalent to Saxenda®, implying its concentration falls within the claimed range.	¶24; ¶26; ¶40	col. 14:2-4
and wherein said formulation has a pH of from about 7.0 to about 10.0.	The infringement allegation is based on the ANDA filing for a bioequivalent product, implying its pH falls within the claimed range.	¶24; ¶26; ¶40	col. 14:7-10

U.S. Patent No. 8,920,383 Infringement Allegations

The public version of the complaint does not contain a detailed claim chart for the '383 patent. The infringement allegations are based on the device described in Orbicular's ANDA submission Compl. ¶33 Compl. ¶46 The following table summarizes the narrative theory.

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A mechanism for preventing setting of a dose which exceeds the amount of a medicament in a reservoir... comprising:	The complaint alleges that the accused "Orbicular's Device" contains a mechanism that infringes claims 1-13 of the '383 patent.	¶33; ¶46	col. 2:1-5
a piston rod having a threaded outer surface, wherein the piston rod rotates and translates axially forward...	The complaint alleges, based on Orbicular's ANDA, that the accused device contains this element.	¶33; ¶46	col. 2:6-7
a limiter that prevents the setting of a dose which exceeds the amount of medication in a reservoir...	The complaint alleges, based on Orbicular's ANDA, that the accused device contains this element.	¶33; ¶46	col. 9:49-52
a driver defining a passage for the limiter, the driver being coupled to the dose setting member...	The complaint alleges, based on Orbicular's ANDA, that the accused device contains this element.	¶33; ¶46	col. 2:10-14
wherein the limiter is coupled to the driver and the piston rod such that relative rotation...causes the limiter to move towards a stopping position.	The complaint alleges, based on Orbicular's ANDA, that the accused device contains this functionality.	¶33; ¶46	col. 4:25-30

• Identified Points of Contention:
  • Scope Questions: For the '833 patent, infringement appears to be conceded by Defendants, subject to a validity challenge Compl. ¶40 The primary dispute will therefore likely not be over infringement scope but patent validity. For the '383 patent, a central question for the court will be whether the components in the accused device, as described in the ANDA, perform the same function in substantially the same way to achieve the same result as the claimed "limiter," "driver," and "piston rod."
  • Technical Questions: A key evidentiary question for the '383 patent will be the precise mechanical operation of the accused device. The dispute may turn on whether the alleged "limiter" in the accused device is "coupled to the driver and the piston rod" and moves toward a stopping position due to "relative rotation" in the manner required by the claim.

V. Key Claim Terms for Construction

U.S. Patent No. 8,114,833

• The Term: "about"
• Context and Importance: This term is used to qualify the claimed concentration range of propylene glycol ("about 1 mg/ml to about 100 mg/ml") and the pH range ("about 7.0 to about 10.0") in claim 1. Its construction is critical for determining the literal scope of the claims. Practitioners may focus on this term because even a small deviation from the recited numerical range in the accused product could avoid infringement if "about" is construed narrowly.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent does not provide an explicit definition for "about," which may support an argument that the term should be given its ordinary and customary meaning, encompassing a reasonable degree of variance.
  • Evidence for a Narrower Interpretation: The patent's examples disclose formulations with highly specific concentrations, such as 13.7 mg/ml of propylene glycol '833 Patent, col. 19:17-18 A party could argue that these specific examples should inform the scope of "about," limiting it to a narrow range of equivalents around the claimed values.

U.S. Patent No. 8,920,383

• The Term: "limiter"
• Context and Importance: The "limiter" is the central component of the claimed end-of-content mechanism. The definition of this term will be dispositive for infringement, as the accused device must contain a structure that meets the claim's functional and structural requirements for the "limiter."
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent defines the limiter functionally as a component "that prevents the setting of a dose which exceeds the amount of medication in a reservoir" '383 Patent, col. 9:49-52 This functional language could support construing the term to cover any component that performs this role, regardless of its specific form.
  • Evidence for a Narrower Interpretation: The specification discloses specific embodiments of the limiter, such as one having a "threaded outer surface" that engages with the driver '383 Patent, col. 3:13-20 or one having "a plurality of teeth" that engage the housing or driver '383 Patent, col. 3:41-46 A party could argue that the term "limiter" should be construed as being limited to these or structurally similar embodiments.

VI. Other Allegations

• Indirect Infringement: The complaint alleges infringement under 35 U.S.C. § 271(e)(2)(A), which establishes that the submission of an ANDA for a drug claimed in a patent is a statutory act of infringement for the purpose of creating federal court jurisdiction Compl. ¶¶39, 45, 51, 57 The complaint also seeks a declaratory judgment that the future commercial manufacture, use, or sale of the product will infringe under 35 U.S.C. § 271(a) and/or (b) Compl. ¶¶70-75
• Willful Infringement: The complaint alleges that Defendants were aware of the asserted patents at the time the ANDA was submitted, based on the required Paragraph IV certifications sent to the Plaintiff Compl. ¶¶43, 49, 55 On this basis, the complaint seeks a finding that the case is "exceptional" and an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶78

VII. Analyst's Conclusion: Key Questions for the Case

• A primary issue will be one of patent validity: Given that infringement of the '833 formulation patent appears uncontested on the technical merits, the case for that patent will likely depend on whether the Defendants can prove by clear and convincing evidence that the claims are invalid, presumably on grounds such as obviousness over the prior art.
• A second core issue will be one of claim construction and technical scope: For the '383, '953, and '893 device patents, the dispute will center on whether the mechanical components of the accused "Orbicular's Device" fall within the scope of the patent claims. This will require the court to construe key terms like "limiter" and "push button connection" and determine if the accused device's structure and operation are equivalent to what is claimed.
• A key evidentiary question will be the content of the ANDA: As the infringement allegations for the device patents are based on the structure described in the defendants' confidential ANDA submission, the unredacted details of that filing will be the primary evidence for assessing the merits of the infringement claims.